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An AAPS joint face-to-face meeting was held on April 6th, 2016 at MedImmune, Gaithersburg, MD. The meeting
was organized by members of the Steering Committees of the Stability Focus Group, the Pharmaceutical Impurities
Focus Group and the Chemistry, Manufacturing and Controls (CMC) Statistics Focus Group. Twenty two subject-matter-
experts (SME) from the Industry and the Food & Drug Administration (FDA) participated as discussion facilitators or
discussion leaders. The total participants reached 65 people representing various sizes of pharmaceutical companies.
Four contemporary technical topics on analytical approaches to ensure product quality were selected to be discussed
and shared information: (1) Approaches to set release limits and managing method variability; (2) Ensure product
quality through lifecycle management; (3) Best practices for predictive stability programs; and (4) ICH Guideline
M7 and mutagenic impurities.
The purpose of the meeting was to share the best practices in the industry related to the topics; therefore, it is
not intended for the participants to reach a consensus on the key issues discussed. This paper summarizes the
discussions in the meeting.Background
An AAPS joint face-to-face meeting was held on April 6th,
2016 at MedImmune, Gaithersburg, MD. The meeting
was organized by members of the Steering Committees of
the Stability Focus Group, the Pharmaceutical Impurities
Focus Group and the Chemistry, Manufacturing and
Controls (CMC) Statistics Focus Group. Four contem-
porary technical topics were selected to be discussed.
Twenty two subject-matter-experts (SME) from the
Industry and the Food & Drug Administration (FDA)
participated as discussion facilitators or discussion
leaders (AAPS Joint Face-to-Face meeting summary,
6-April-2016, part I; AAPS Joint Face-to-Face meeting
summary, 6-April-2016, part II).* Correspondence: kim.huynhba@pharmalytik.com
Pharmalytik LLC, Newark, DE, USA
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the Creative Commons license, and indicate ifTopic A: Approaches to set release limits and managing
method variability towards ensuring product quality
ICH Q1E provides regulatory guidance for calculating
shelf life of a drug product or retest period of a drug
substance based on stability data utilizing simple statistical
approaches. To ensure that the drug products manufac-
tured over the life cycle consistently meet the registered
specification during its shelf life, it is important to have an
internal control limit for the assay that factors in typical
manufacturing and analytical variabilities. This is typically
called “release limit” which is a range of potency within
which an individual lot can be released to market ensuring
that its potency will remain within registered specification
limits throughout the shelf life. Thus “release limit” pro-
vides an internal control for ensuring product quality
(Fig. 1). The impurity level increases over the shelf life as a
combination of the loss of active and the uncertainty ofis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Release Limit as an internal control
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have been described for calculating release limits, a com-
monly used one is Allen, Dukes and Gerger method (Allen
et al. 1991). There is an inconsistency in establishing har-
monized control strategies for release limit from organiza-
tions working globally.
The participants agreed that development of a release
limit is critical for controlling the product quality; how-
ever, the data utilized and procedure used to determine
an appropriate release limit is not consistent. This is not
unexpected since release limit is an internal control par-
ameter. The following points were raised and discussed
by the participants.
1. The stability profile of the drug product shows
change over time, the typical variabilities in stability
profile are incorporated in the calculation of shelf
life by ICH Q1E. The regression/covariance approach
described in ICH Q1E is one way of characterizing
the stability change over time and its associated
variability. The shelf life is a key factor in the
calculation of release limit. Manufacturing data
can be used to assess the capability of meeting
the calculated limit based (based on the distribution/
histogram of Fig. 1), but it is not a component of
the calculation. One must work backwards-given
a shelf life, changes in stability profile over time,
specification range for assay and impurities,
manufacturing variability and the uncertainty in
calculation of a release limit following the Allen,
Duke, Gerger approach (Allen et al. 1991).2. The drug substance stability profile is important.
The maximum allowed level of impurities in the
drug substance is an important consideration. Typically
the drug substance attribute (assay) is used in
formulating the batch during manufacture.
3. Analytical variability is an important consideration.
The typical analytical variability as established during
method validation should be considered in calculating
the release limit.
The participants agreed that having an appropriate re-
lease limit would ensure consistent quality of the drug
product through the shelf life and thus protect the
manufacturer and the patient. It is important to have
batch data from significant number of commercial
batches using the final process in calculating the release
limit. When a release value falls outside of a release
limit, the quality system will prompt an investigation
and mitigation procedure will be developed.
In summary, the majority of the companies used cer-
tain released limits; of those, approximately 50% uses
statistical approaches to establish release limits, others
use a variety of alternative methods; however, specific
non-statistical approaches were not discussed. However,
it was concurred that we need to establish a common
understanding of terminology.
Topic B: Strategies for ensuring global product quality
through effective life cycle management
The Guidance for Industry entitled “Analytical Proce-
dures and Methods Validation for Drugs and Biologics”
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Drug Adminstration, Guidance for Industry 2015).
Participants discussed the key challenges experienced
in product lifecycle management and best practices.
They shared typical experiences with analytical methods
lifecycle supporting product lifecycle management and
explored best approaches to global product lifecycle
management.
1. Several large pharma companies have developed
systematic analytical quality-by-design (AQbD)
approach for small and large molecule areas.
This approach adds significant value to method
development by defining and understanding critical
method attributes, critical method parameters, and
method operable design region. Based on the
experiences by several companies, it was recognized
that regulatory flexibility cannot be realized at
this time from AQbD based method development
and validation consistent with ICH Q8, 9 and 10.
(International Conference on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use & Q8 (R2) 2009;
International Conference on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use & Q9 2005;
International Conference on Harmonisation
of Technical Requirements for Registration of
Pharmaceuticals for Human Use & Q10 2008)
Best practices were discussed on clinical phase-
appropriate method validation approaches to
support product development as follows:
 Phase I: Simplified documentation practices, for
example, scientific method qualification plans
are used in place of formal protocols; platform
standard method conditions are used demonstrating
that the methods are fit-for-purpose at this phase.
 Phase II: general protocols issued by analytical
development groups, pre-approved template
protocols are used by several companies,
demonstrate that the methods are fit-for-purpose.
 Phase III: formal protocols, QA approved; fully
validated methods
2. Science and risk-based approach should be used
to drive better decision making for current product
development process. It is important to balance
the needs of method changes, technology/process
improvement, and manufacturing site changes, etc.
with product understanding and regulatory expectations
to ensure consistent product quality throughout the
lifecycle. The following issues were discussed:
2.1 Possibility of obtaining regulatory flexibility from
AQbD-based method development was dis-
cussed; however, it was recognized thatregulatory flexibility is not typically granted by
most agencies at this time.
2.2 FDA often observes additional development
activities after approval; and request for introduction
of the changes in analytical methods and process are
made. It was recognized that introduction of newer
analytical technologies may be beneficial to ensure
consistency of product quality throughout the
product lifecycle. However, it was agreed that
when analytical methods based on newer
technologies (e.g., UPLC, SFC etc.) are proposed
for commercial products, one needs to consider
the lead time and build a business case (time
saving, training needs, implementation feasibility
etc.) for introducing the technology. Commercial
sites are heavily invested in established technologies
both in capital equipment and staff training;
therefore planning to implement a new technology
into an established, multi-product, facility may take
2 years or more of lead time.
2.3 Predictive or accelerated stability studies may be
considered for annual stability batches to help
monitor process control and identify potential
issues early. Several participants also discussed
success in gaining regulatory approval for “Lean
stability approach” (e.g., stability protocol limited
to monitoring parameters that changes on storage)
as post approval changes with adequate data
including process control and scientific justification.
Regulatory SME’s concurred that with sufficient
data and clear justification, stability protocols for
post-approval annual stability batches can be “lea-
ner” and have “non-value-added” tests eliminated.
2.4 For biologic development, it was noted that
accelerated (unfrozen) API stability studies as
compared to frozen API are very informative for
identifying potential changes to be anticipated;
however, it is not necessary for formal stability
protocol. Such studies are also useful for
understanding potential impact of short
temperature excursions resulting from handling of
the API for normal use over the life of a batch.
Frozen API is inherently stable, thus long term
stability study does not add much scientific value.
(Kochling et al. 2016)
3. Opportunities and challenges of meeting evolving
regulatory requirements and compliance standards
in a global environment
3.1 Life cycle management of a global product often
requires managing multiple specifications required
for different countries (International Conference
on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use,
Q12 Concept Paper 2014). Best practices to
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different companies were discussed. It was
concurred that companies need to think both
global (for general strategy) and local (for meeting
specific local country-specific requirements)
simultaneously. Pfizer has coined the term “Glo-
cal” to encourage such thinking. To manage mul-
tiple specifications, some companies maintain
one specification that meet or exceed specifi-
cation requirements of each country, others
manage individual country specifications. Multi-
specification approach adds significant complica-
tion to managing commercial supply chain.
3.2When multiple specifications are needed for
products in different markets, companies typically
test to the tightest specification. With this practice,
one set of release test data meets all global
specification requirements. In addition, with
this practice, the innovators may hold their
products to a tighter specifications compared to
generics, which may be approved for a specific
market that allows less rigorous specifications. It
is noted that while regulatory agencies observe
and review each other’s approval decisions, FDA
makes their own decision independent of other
agencies’ decisions.Table 1 Example of challenges encountered using predictive
stability studies
• Mistrust of models–lack of understanding–or too complex to model
• Lack of broad champion
• Lack of resources or different use of resources
• Lack of knowledge on approach
• Risk aversion
• Data quality is questioned if using low levels
• Product is too stable–difficult to develop predictive degradant
model when change is small relative to noise
• If modeling is not successful for a product it may cast doubt on
other products
• Challenges modeling dissolutionOverall, the attendees concurred that lifecycle man-
agement approaches for global products present sig-
nificant challenges and there are differences in the
best practices among companies. It was agreed that
further discussions on this subject in future forums
will be very beneficial.
Topic C: Challenges and Best Practices for Successful
Predictive Stability Programs (small molecules and large
molecules)
Predictive stability has long been used to quickly generate
information to make timely and science-based decisions.
At each breakout session, a case study of implementa-
tion was presented to highlight a successful approach
to the topic and illustrate how these data can be lever-
aged for better decision making and/or time and re-
source savings. For example, when there is no physical
changes in the dosage form occur, then the Arrhenius
model for chemical reaction can be used. However,
when physical changes occur, the reaction rates typic-
ally do not follow Arrhenius model, then a model can
be designed to predict stability profile throughout the
expiration dating period. With such model, predictive
stability studies can support the selection of packages
and/or formulations, to justify excursions and provide
insight on in-use stability (Genton & Kesselring 1977;
Waterman et al. 2007). In addition, these data couldalso be used to justify the retest period for clinical trial
material and to justify lean post-approval protocols.
Predictive stability data can also be used to help in the
establishment of degradation mechanism, identification
of the degradation pathways, development of stability in-
dicating method, and to support accelerated develop-
ment programs. Development of these predictive models
is very beneficial to gain a better understanding of how
the product behaves on long term stability. However, the
implementation of predictive stability study faces chal-
lenges. Table 1 list examples of challenges that have been
encountered. For example, one is working with a stable
product, thus changes on stability is not significant.
Therefore, it would be difficult to develop an accurate
predictive model as these minute changes can be con-
cealed by noise. There is also a fear that an unsuccessful
model can cast doubt on activities of other products.
Different approaches are recommended to overcome
resistance of using predictive models. One is to conduct
an initial study to determine critical activities. Risks can
also be reduced by running additional tests outside of
formal stability program and providing data or setting
up testing if challenged by a regulatory agency. Partici-
pants also discussed unique issues pertaining to large
versus small molecules development. Table 2 lists the
typical issues presented. For example, Arrhenius model
is not applicable for large molecules or the variability of
quantitate methods for biologics is too large and make it
difficult to narrow down to a precise predictive model.
Other challenges would be non-linear model of which
extrapolation from accelerated condition to label storage
condition becomes risky.
Flexibility in data reporting was also discussed as it
can be key to enable successful predictive stability pro-
grams. It is noted that reporting below Limit of Quanti-
tation (LOQ) can provide several advantages. Extra
decimal places can also be helpful; however, this can be
a barrier as there may be challenges with existing LIMS
Table 2 Unique issues for large versus small molecules
• Applicability of Arrhenius equation for large molecules
• Perceived need to start with first principles
• Variability for biologics may make it more difficult to precisely model
• Fundamental model selection for biologics
• Lack of trust of non-linear models
• Temperature and/or Humidity is too high thus modeling is not predictive.
• Physical changes/polymorph changes–modeling in solids
• Modeling is difficult for proteins in solution–reversible step vs irreversible
steps
• Label condition for Biologic drug substances is -20C – >what is
accelerated?
• Extrapolation can be risky
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Detection but below LOQ.
Best practices were recommended to use multiple
preparations rather than multiple injections when repli-
cation was desired to reduce variability and improve es-
timation. When possible, it was recommended to hold
samples and test together on one run to remove day to
day variability. It was also noted that variability of bio-
logic testing may make it difficult to develop a precise
predictive model.
Overall, all agreed that significant opportunities exist
to leverage predictive stability; however, one should start
with a small program and build upon successes to grow
the program. This topic seems to gain much interest
from participants and warrants future discussion for
industry and regulatory perspectives.
Topic D: ICH M7 and Mutagenic Impurities
This group started by presenting the scope of the ICH
M7 guideline (International Conference on Harmonisa-
tion of Technical Requirements for Registration of Phar-
maceuticals for Human Use, M7 (R1) 2015). It applies toFig. 2 Framework for M7 Guidelinenew drug substance and drug product during clinical de-
velopment and subsequent applications for marketing,
as well as specific cases of post-approval submissions of
marketed products and to new marketing applications.
Figure 2 shows the general framework of the guideline
(Miller et al. 2015).
This guideline provides assessment on potential im-
purities such as starting materials, reagents and interme-
diates downstream of the starting material, in addition
to other identified impurities. Actual impurities are
those that have been identified as per levels stated in
ICH Q3A/B.
Both potential and actual impurities should undergo a
hazard assessment to determine their classification (-6)
with respect to mutagenic and carcinogenic potential and
then undergo a risk characterization to set appropriate
limits. For Class 1, 2 and 3 impurities, ICH M7 guideline
provided the principles of risk characterization that are
used to derive acceptable intakes (Table 3).
Four options to control potential impurities are
discussed.
1. Monitor the impurity in the drug substance with
acceptance criteria ≤ acceptable limit
2. Monitor the impurity in the intermediate, starting
material or in-process control with acceptance
criteria ≤ acceptable limit
3. Include impurity on a starting material, intermediate
or in-process control specification with an acceptance
criteria above the acceptable limit coupled with well
understood purge.
4. No testing, control assured via chemistry and process
understanding
This group concluded by discussing and clarifying
the scope of the guidance, i.e. excipients, impurities
in biologics, if the impurity is a small molecule. It
was noted that communication across disciplines (e.g.
Table 3 Risk characterization for acceptable intake levels
• TTC-based acceptable intakes
• Develop compound-specific limits when carcinogenicity data available
• Acceptable intakes based on compound-specific risk assessments
• Acceptable intakes based on Less than lifetime (staged TTC) limit concept
• Acceptable total daily intakes for multiple impurities
• Exceptions and flexibility in approaches
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ate controls are in place, especially since dose levels
may change or the drug may be used in combination
with others or for a different indication. Challenges
with analytical method, e.g. method transfer, capabil-
ities of QC lab, were noted. There was much discus-
sion around when to identify an impurity and when
to perform a toxicology assessment using Quantitative
Structure-Activity Relationship ((Q)SAR) method, e.g.
whether to wait until the impurity is confirmed or
decide it should be routinely done at certain phase of
development. Inclusion of information in the filing,
i.e. stage dependence, placement, materials/reagents
prior to route disclosed also discussed.
Discussion also included the use of (Q)SAR software.
Participants shared that FDA recommended to report
the model name, version, description, methodology and
outcome. Additional scientific justification needed if
Sponsor is “over-ruling” the result by (Q)SAR method. It
is noted that FDA uses the most recent (Q)SAR software
version; therefore, as feasible, Sponsors may consider re-
running predictions for impurities above threshold when
a new software version is released. Although ICH M7
clearly states when assessment needs to be done on a
marketed product, Sponsors have seen some queries
particularly from EMA requesting assessment even when
not warranted as per the guidance.
Suggestion was made for the Pharmaceutical Impur-
ities Focus Group to consider a technical session to dis-
cuss real world problems in implementing ICH M7 such
as best demonstrated practices, Agency recommenda-
tions, and case studies to continue this discussion.
Overall conclusion
The meeting was concluded on a high note. Participants
appreciated the opportunity to have face-to-face interac-
tions with multiple subject-matter-experts from the in-
dustry and FDA representatives. Technical information
and common practices are shared and received positively
at all breakout sessions. It is not expected for partici-
pants to reach a consensus due to the time limita-
tions. The three sponsored AAPS Focus Groups have
developed several plans to continue the discussion of
these critical topics at upcoming AAPS annual meet-
ing and workshop.Acknowledgements
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